1
|
Chen R, Zhou C, Pang X, Liu J, Gu Y, Liu J, Li Z. Design, Synthesis, Anti-cancer Activities and Computational Analysis of Novel Diamides Conformationally Restricted by Cyclopropane. CHINESE J ORG CHEM 2022. [DOI: 10.6023/cjoc202106053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
2
|
Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P. Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. J Med Chem 2021; 64:14773-14792. [PMID: 34613725 DOI: 10.1021/acs.jmedchem.1c01356] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
MGAT2 inhibition is a potential therapeutic approach for the treatment of metabolic disorders. High-throughput screening of the BMS internal compound collection identified the aryl dihydropyridinone compound 1 (hMGAT2 IC50 = 175 nM) as a hit. Compound 1 had moderate potency against human MGAT2, was inactive vs mouse MGAT2 and had poor microsomal metabolic stability. A novel chemistry route was developed to synthesize aryl dihydropyridinone analogs to explore structure-activity relationship around this hit, leading to the discovery of potent and selective MGAT2 inhibitors 21f, 21s, and 28e that are stable to liver microsomal metabolism. After triaging out 21f due to its inferior in vivo potency, pharmacokinetics, and structure-based liabilities and tetrazole 28e due to its inferior channel liability profile, 21s (BMS-963272) was selected as the clinical candidate following demonstration of on-target weight loss efficacy in the diet-induced obese mouse model and an acceptable safety and tolerability profile in multiple preclinical species.
Collapse
|
3
|
Xie F, Yang F, Liang Y, Li L, Xia Y, Jiang F, Liu W, Qi Y, Chowdhury SR, Xie D, Fu L. Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors. Eur J Med Chem 2019; 164:408-422. [DOI: 10.1016/j.ejmech.2018.12.032] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 12/11/2018] [Accepted: 12/14/2018] [Indexed: 01/03/2023]
|
4
|
Fatahala SS, Mahgub S, Taha H, Abd-El Hameed RH. Synthesis and evaluation of novel spiro derivatives for pyrrolopyrimidines as anti-hyperglycemia promising compounds. J Enzyme Inhib Med Chem 2019; 33:809-817. [PMID: 29708461 PMCID: PMC6009929 DOI: 10.1080/14756366.2018.1461854] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Affiliation(s)
- Samar Said Fatahala
- a Pharmaceutical Organic Chemistry Department , Helwan University , Helwan , Cairo , Egypt
| | - Shahenda Mahgub
- b Biochemistry Department, Faculty of Pharmacy , Helwan University , Helwan , Cairo , Egypt
| | - Heba Taha
- b Biochemistry Department, Faculty of Pharmacy , Helwan University , Helwan , Cairo , Egypt
| | | |
Collapse
|
5
|
Abstract
In classical medicinal chemistry, nitrile groups were commonly considered as bioisosteres of carbonyl, hydroxyl and carboxyl groups, as well as halogen atoms. However, there is a lack of in-depth understanding about the structural and energetic characteristics of nitrile groups in protein–ligand interactions. Here, we have surveyed the Protein Data Bank and ChEMBL databases with the goal of characterizing such protein–ligand interactions for nitrile-containing compounds. We discuss the versatile roles of nitrile groups in improving binding affinities, and give special attention to examples of displacing and mimicking binding-site waters by nitrile groups. We expect that this review article will further inspire medicinal chemists to exploit nitrile groups rationally in structure-based drug design.
Collapse
|
6
|
Shi J, Gu Z, Jurica EA, Wu X, Haque LE, Williams KN, Hernandez AS, Hong Z, Gao Q, Dabros M, Davulcu AH, Mathur A, Rampulla RA, Gupta AK, Jayaram R, Apedo A, Moore DB, Liu H, Kunselman LK, Brady EJ, Wilkes JJ, Zinker BA, Cai H, Shu YZ, Sun Q, Dierks EA, Foster KA, Xu C, Wang T, Panemangalore R, Cvijic ME, Xie C, Cao GG, Zhou M, Krupinski J, Whaley JM, Robl JA, Ewing WR, Ellsworth BA. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. J Med Chem 2018; 61:681-694. [DOI: 10.1021/acs.jmedchem.7b00982] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Jun Shi
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Zhengxiang Gu
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Elizabeth Anne Jurica
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Ximao Wu
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Lauren E. Haque
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Kristin N. Williams
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Andres S. Hernandez
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Zhenqiu Hong
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Qi Gao
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Marta Dabros
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Akin H. Davulcu
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Arvind Mathur
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Richard A. Rampulla
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Arun Kumar Gupta
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Ramya Jayaram
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Atsu Apedo
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Douglas B. Moore
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Heng Liu
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Lori K. Kunselman
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Edward J. Brady
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Jason J. Wilkes
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Bradley A. Zinker
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Hong Cai
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Yue-Zhong Shu
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Qin Sun
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Elizabeth A. Dierks
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Kimberly A. Foster
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Carrie Xu
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Tao Wang
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Reshma Panemangalore
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Mary Ellen Cvijic
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Chunshan Xie
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Gary G. Cao
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Min Zhou
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - John Krupinski
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Jean M. Whaley
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Jeffrey A. Robl
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - William R. Ewing
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| | - Bruce Alan Ellsworth
- Research and Development, Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States
| |
Collapse
|
7
|
Zheng Y, Yu X, Lv S, Mykhailiuk PK, Ma Q, Hai L, Wu Y. Synthesis of CHF2-substituted 3-azabicyclo[3.1.0]hexanes by photochemical decomposition of CHF2-pyrazolines. RSC Adv 2018; 8:5114-5118. [PMID: 35558341 PMCID: PMC9092616 DOI: 10.1039/c7ra13141k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Accepted: 01/23/2018] [Indexed: 12/28/2022] Open
Abstract
A practical synthesis of CHF2-substituted 3-azabicyclo[3.1.0]hexanes was developed for the first time. The key step was photochemical decomposition of CHF2-substituted pyrazolines. This protocol has the advantages of simple operation, and mild conditions, as well as excellent functional group tolerance, giving the desired products in moderate to excellent yields. A general and efficient method has been developed to synthesize CHF2-substituted 3-azabicyclo[3.1.0]hexane derivatives via photochemical decomposition of CHF2-pyrazolines.![]()
Collapse
Affiliation(s)
- Yang Zheng
- Key Laboratory of Drug-Targeting of Education Ministry
- Department of Medicinal Chemistry
- West China School of Pharmacy
- Sichuan University
- Chengdu 610041
| | - Xinling Yu
- Key Laboratory of Drug-Targeting of Education Ministry
- Department of Medicinal Chemistry
- West China School of Pharmacy
- Sichuan University
- Chengdu 610041
| | - Songyang Lv
- Key Laboratory of Drug-Targeting of Education Ministry
- Department of Medicinal Chemistry
- West China School of Pharmacy
- Sichuan University
- Chengdu 610041
| | - Pavel K. Mykhailiuk
- Enamine Ltd
- 01103 Kyiv
- Ukraine
- Taras Shevchenko National University of Kyiv Chemistry Department
- 01601 Kyiv
| | - Qiang Ma
- Key Laboratory of Drug-Targeting of Education Ministry
- Department of Medicinal Chemistry
- West China School of Pharmacy
- Sichuan University
- Chengdu 610041
| | - Li Hai
- Key Laboratory of Drug-Targeting of Education Ministry
- Department of Medicinal Chemistry
- West China School of Pharmacy
- Sichuan University
- Chengdu 610041
| | - Yong Wu
- Key Laboratory of Drug-Targeting of Education Ministry
- Department of Medicinal Chemistry
- West China School of Pharmacy
- Sichuan University
- Chengdu 610041
| |
Collapse
|
8
|
Lo JC, Kim D, Pan CM, Edwards JT, Yabe Y, Gui J, Qin T, Gutiérrez S, Giacoboni J, Smith MW, Holland PL, Baran PS. Fe-Catalyzed C-C Bond Construction from Olefins via Radicals. J Am Chem Soc 2017; 139:2484-2503. [PMID: 28094980 PMCID: PMC5314431 DOI: 10.1021/jacs.6b13155] [Citation(s) in RCA: 275] [Impact Index Per Article: 39.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
![]()
This Article details the development
of the iron-catalyzed conversion
of olefins to radicals and their subsequent use in the construction
of C–C bonds. Optimization of a reductive diene cyclization
led to the development of an intermolecular cross-coupling of electronically-differentiated
donor and acceptor olefins. Although the substitution on the donor
olefins was initially limited to alkyl and aryl groups, additional
efforts culminated in the expansion of the scope of the substitution
to various heteroatom-based functionalities, providing a unified olefin
reactivity. A vinyl sulfone acceptor olefin was developed, which allowed
for the efficient synthesis of sulfone adducts that could be used
as branch points for further diversification. Moreover, this reactivity
was extended into an olefin-based Minisci reaction to functionalize
heterocyclic scaffolds. Finally, mechanistic studies resulted in a
more thorough understanding of the reaction, giving rise to the development
of a more efficient second-generation set of olefin cross-coupling
conditions.
Collapse
Affiliation(s)
- Julian C Lo
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Dongyoung Kim
- Department of Chemistry, Yale University , 225 Prospect Street, New Haven, Connecticut 06520, United States
| | - Chung-Mao Pan
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Jacob T Edwards
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Yuki Yabe
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Jinghan Gui
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Tian Qin
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Sara Gutiérrez
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Jessica Giacoboni
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Myles W Smith
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Patrick L Holland
- Department of Chemistry, Yale University , 225 Prospect Street, New Haven, Connecticut 06520, United States
| | - Phil S Baran
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
9
|
Abstract
Diabetes mellitus is a chronic disease affecting patients' daily life and increasing patients' risk of other complication. Dipeptidyl peptidase-4 (DPP-4) is a serine aminopeptidase, which is one of the validated targets for Type 2 diabetes therapy due to its regulatory effect of incretin hormone. Seven DPP-4 inhibitors are commercially available nowadays on the market as Type 2 diabetes drugs. They are all chemically synthesized compounds with good therapeutic effects, but long-term safety remains unknown. On the other hand, nature provides a rich source for search of desired safe and effective medications; and actually more than half of the drugs on market are natural product related. Therefore, a systematic search for new DPP-4 inhibitors from nature sources seems to be of great utility for developing novel antidiabetic drugs. This review summarized recent progress of DPP-4 inhibitors from natural products, revealed that both pure natural products and the crude extracts of herbs or the hydrolyzates of proteins are active as DPP-4 inhibitors. Therefore, both could be served as useful clues for developing next generation of antidiabetes medicines via inhibiting DPP-4 activity.
Collapse
|
10
|
Paladino M, Zaifman J, Ciufolini MA. Total Synthesis of (+)-3-Demethoxyerythratidinone and (+)-Erysotramidine via the Oxidative Amidation of a Phenol. Org Lett 2015; 17:3422-5. [DOI: 10.1021/acs.orglett.5b01423] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Marco Paladino
- Department of Chemistry, The University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
| | - Joshua Zaifman
- Department of Chemistry, The University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
| | - Marco A. Ciufolini
- Department of Chemistry, The University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
| |
Collapse
|
11
|
Wacker DA, Wang Y, Broekema M, Rossi K, O'Connor S, Hong Z, Wu G, Malmstrom SE, Hung CP, LaMarre L, Chimalakonda A, Zhang L, Xin L, Cai H, Chu C, Boehm S, Zalaznick J, Ponticiello R, Sereda L, Han SP, Zebo R, Zinker B, Luk CE, Wong R, Everlof G, Li YX, Wu CK, Lee M, Griffen S, Miller KJ, Krupinski J, Robl JA. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J Med Chem 2014; 57:7499-508. [PMID: 25208139 DOI: 10.1021/jm501175v] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic β-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. This dual mechanism of action has generated significant interest in the discovery of small molecule GPR119 agonists as a potential new treatment for type 2 diabetes. Herein, we describe the discovery and optimization of a new class of pyridone containing GPR119 agonists. The potent and selective BMS-903452 (42) was efficacious in both acute and chronic in vivo rodent models of diabetes. Dosing of 42 in a single ascending dose study in normal healthy humans showed a dose dependent increase in exposure and a trend toward increased total GLP-1 plasma levels.
Collapse
Affiliation(s)
- Dean A Wacker
- Departments of Discovery Chemistry, Metabolic Diseases, Lead Evaluation, Computer-Assisted Drug Design, Discovery Toxicology, Exploratory Clinical and Translational Research, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb , P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Tanwar O, Deora GS, Tanwar L, Kumar G, Janardhan S, Alam M, Akhter M. Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations. J Mol Model 2014; 20:2118. [PMID: 24687332 DOI: 10.1007/s00894-014-2118-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2013] [Accepted: 12/14/2013] [Indexed: 11/26/2022]
Abstract
The present study demonstrates and validates the discovery of two novel hydrazine derivatives as selective dipeptidyl peptidase-IV (DPP-IV) inhibitors. Virtual screening (VS) of publicly available databases was performed using virtual screening workflow (VSW) of Schrödinger software against DPP-IV and the most promising hits were selected. Selectivity was further assessed by docking the hits against homology modeled structures of DPP8 and DPP9. Two novel hydrazine derivatives were selected for further studies based on their selectivity threshold. To assess their correct binding modes and stability of their complexes with enzyme, molecular dynamic (MD) simulation studies were performed against the DPP-IV protein and the results revealed that they had a better binding affinity towards DPP-IV as compared to DPP 8 and DPP 9. The binding poses were further validated by docking these ligands with different softwares (Glide and Gold). The proposed binding modes of hydrazines were found to be similar to sitagliptine and alogliptine. Thus, the study reveals the potential of hydrazine derivatives as highly selective DPP-IV inhibitors.
Collapse
Affiliation(s)
- Omprakash Tanwar
- Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Bioinformatics Infrastructure Facility (BIF), Jamia Hamdard, New Delhi, 110062, India
| | | | | | | | | | | | | |
Collapse
|
13
|
Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG. Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem 2013; 56:7343-57. [DOI: 10.1021/jm4008906] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Pratik Devasthale
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Ying Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Wei Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - John Fevig
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - JianXin Feng
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Aiying Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Tom Harrity
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Don Egan
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Nathan Morgan
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Michael Cap
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Aberra Fura
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Herbert E. Klei
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Kevin Kish
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Carolyn Weigelt
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Lucy Sun
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Paul Levesque
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Frederic Moulin
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Yi-Xin Li
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Robert Zahler
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Mark S. Kirby
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| | - Lawrence G. Hamann
- Metabolic Diseases Chemistry, ‡Metabolic Diseases
Biology, §Pharmaceutical
Candidate Optimization, ∥Protein Science and Structure, ⊥Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-5400, United States
| |
Collapse
|
14
|
Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 2013; 113:3516-604. [PMID: 23432396 PMCID: PMC3650105 DOI: 10.1021/cr100264t] [Citation(s) in RCA: 439] [Impact Index Per Article: 39.9] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Lukas Wanka
- Institute of Organic Chemistry, Justus-Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; Fax +49(641)9934309
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
| | - Khalid Iqbal
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
| | - Peter R. Schreiner
- Institute of Organic Chemistry, Justus-Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; Fax +49(641)9934309
| |
Collapse
|
15
|
Nitta A, Fujii H, Sakami S, Satoh M, Nakaki J, Satoh S, Kumagai H, Kawai H. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2012; 22:7036-40. [DOI: 10.1016/j.bmcl.2012.09.099] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Revised: 09/24/2012] [Accepted: 09/26/2012] [Indexed: 01/19/2023]
|
16
|
Wang W, Devasthale P, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Li YX, Zahler R, Kirby MS, Hamann LG. 7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site. Bioorg Med Chem Lett 2011; 21:6646-51. [DOI: 10.1016/j.bmcl.2011.09.074] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Revised: 09/16/2011] [Accepted: 09/19/2011] [Indexed: 10/17/2022]
|
17
|
Tactics for the asymmetric preparation of 2-azabicyclo[3.1.0]hexane and 2-azabicyclo[4.1.0]heptane scaffolds. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.03.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
18
|
Synthesis of 5-substituted-3,4-dihydroxycyanopyrrolidines. An easy access to polyhydroxyprolines. Tetrahedron 2009. [DOI: 10.1016/j.tet.2009.01.108] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 2009; 17:1783-802. [PMID: 19217790 DOI: 10.1016/j.bmc.2009.01.061] [Citation(s) in RCA: 146] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2008] [Revised: 01/21/2009] [Accepted: 01/24/2009] [Indexed: 12/25/2022]
|
20
|
Nitta A, Fujii H, Sakami S, Nishimura Y, Ohyama T, Satoh M, Nakaki J, Satoh S, Inada C, Kozono H, Kumagai H, Shimamura M, Fukazawa T, Kawai H. (3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2008; 18:5435-8. [DOI: 10.1016/j.bmcl.2008.09.042] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2008] [Revised: 08/26/2008] [Accepted: 09/09/2008] [Indexed: 01/08/2023]
|